Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jul 1;117(7):1158-1161.
doi: 10.14309/ajg.0000000000001735. Epub 2022 Mar 16.

Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects

Loren Laine  1   2 , Prateek Sharma  3 , Darcy J Mulford  4 , Barbara Hunt  4 , Eckhard Leifke  4 , Neila Smith  4 , Colin W Howden  5
Affiliations
Randomized Controlled Trial

Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects

Loren Laine et al. Am J Gastroenterol. .

Abstract

Introduction: We assessed pharmacodynamics and pharmacokinetics of a potassium-competitive acid blocker and proton pump inhibitor in US subjects.

Methods: Healthy adults were randomized to 7-day periods of vonoprazan 20 mg once daily followed by lansoprazole 30 mg once daily or the reverse order, separated by ≥ 7 days of washout.

Results: Vonoprazan (N = 40) had higher proportions of 24-hour periods with intragastric pH > 4 than lansoprazole (N = 41,38) on day 1 (62.4% vs 22.6%, P < 0.0001) and day 7 (87.8% vs 42.3%, P < 0.0001). Separation in pH started ∼2.5 hours after the first dose.

Discussion: Vonoprazan provided more rapid and potent inhibition of intragastric acidity than lansoprazole in US subjects.

Trial registration: ClinicalTrials.gov NCT04729101.

PubMed Disclaimer

Comment in

References

    1. Abdel-Aziz Y, Metz DC, Howden CW. Review article: Potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther 2021;53:794–809.
    1. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013;19:25–35.
    1. Scott DR, Helander HF, Hersey SJ. The site of acid secretion in the mammalian parietal cell. Biochim Biophys Acta 1993;1146:73–80.
    1. Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther 2015;42:1315–26.
    1. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015;41:636–48.

Publication types

Associated data